In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics
Molecules · 2025
DOI: 10.3390/molecules30061226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Julia J Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Epigenomic Medicine Laboratory at prospED Polytechnic, Carlton, VIC 3053, Australia. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Receptors, Mineralocorticoid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Victorian Government’s Operational Infrastructure Scheme.
Abstract (Originalsprache)
The mineralocorticoid receptor (MR) is a steroid hormone receptor that plays a key role in regulating sodium and water homeostasis and blood pressure. MR antagonists are a guideline recommended for therapy for the treatment of hypertension and cardiovascular disease but can cause hyperkalaemia. Modelling was performed for binding of the endogenous ligands aldosterone and cortisol and MR antagonist spironolactone to the ligand binding domain (LBD) of the MR. A molecular docking screen of compounds that were structurally similar to known antagonists was performed, leading to the identification of two novel compounds, C79 and E67. Molecular dynamics (MD) assessed the dynamic interactions with C79, E76, endogenous ligands, and spironolactone with the MR ligand binding domain (LBD). Analysis of the protein backbone showed modest changes in the overall structure of the MR LBD in response to binding of antagonists, with movement in helix 12 consistent with previous observations. All ligands tested maintained stable binding within the MR LBD throughout the simulations. Hydrogen bond formation played a more prominent role in the binding of endogenous ligands compared to antagonists. MM-PBSA binding free energy calculations showed that all ligands had similar binding affinities, with binding facilitated by key residues within the binding site. The novel antagonists demonstrated similar binding properties to spironolactone, warranting further evaluation. This study provides insights into the molecular mechanisms of MR activation and inhibition, which can aid in the development of novel therapeutic strategies for cardiovascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Epigenomic Medicine Laboratory at prospED Polytechnic, Carlton, VIC 3053, Australia.
- Epigenetics in Human Health and Disease Program, Baker Heart and Diabetes Institute, 75 Commercial Road, Prahran, VIC 3004, Australia.
- Department of Microbiology and Immunology, The University of Melbourne, Parkville, VIC 3010, Australia.
- School of Science, STEM College, RMIT University, Melbourne, VIC 3001, Australia.
- Baker Department of Cardiometabolic Health, The University of Melbourne, Parkville, VIC 3010, Australia.
- Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.
ORCID-Profile: Julia J Liang, Andrew Hung, Assam El-Osta, Tom C Karagiannis, Morag J Young
Förderung
- Victorian Government’s Operational Infrastructure Scheme
Zitieren
APA
Liang, J. J., Cao, S., Hung, A., El-Osta, A., Karagiannis, T. C., & Young, M. J. (2025). In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics. Molecules. https://doi.org/10.3390/molecules30061226
Vancouver
Liang JJ, Cao S, Hung A, El-Osta A, Karagiannis TC, Young MJ. In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics. Molecules. 2025. doi:10.3390/molecules30061226
BibTeX
@article{Liang2025,
author = {Liang, Julia J and Cao, Sara and Hung, Andrew and El-Osta, Assam and Karagiannis, Tom C and Young, Morag J},
title = {In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30061226}
}
EUVIMED